Head and Neck Cancer Trial, Recruiting NCT07412314 Sponsor: Guangzhou Concord Cancer Center Condition: Head and Neck Cancer
Back to Head And Neck Cancer

Head and Neck Cancer Trial, Recruiting

NCT07412314
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who have been diagnosed with squamous cell carcinoma (a type of cancer) of the nasopharynx (the upper part of the throat, behind the nose), confirmed by a biopsy, at a certain stage of advancement — either at stage T2b or higher, and/or where the cancer has spread to nearby lymph nodes
  • People whose cancer type falls within WHO pathological types I, II, or III (a classification system used to describe the type of nasopharyngeal cancer cells) (confirm with trial site)
  • People who are aged 18 or older
  • People who have a good general level of physical functioning, rated 0 or 1 on a standard medical scale (meaning able to carry out normal daily activities with little or no limitation)
  • People whose doctors expect them to live for at least 6 months
  • People whose tumour has been assessed and measured before treatment begins
  • People who are well-nourished and healthy enough physically to tolerate both radiation therapy and chemotherapy

Who may not be able to join:

  • People whose cancer has spread to distant parts of the body (known as stage IVc, or distant metastasis)
  • People where the cancer has come back only in the lymph nodes in the neck
  • People who are currently participating in, or have previously participated in, another interventional clinical trial for cancer treatment
  • People who have had another type of cancer (other than a certain type of skin cancer called non-melanoma skin cancer) within the past 5 years, or who have had a cancer that started in the head or neck region
  • People who have an active infection that is currently untreated

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 21 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Yuan Taize, private hospital

Phone: 8620-32506195

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Guangzhou Concord Cancer Center
Registry
ClinicalTrials.gov
Start date
10 March 2025
Est. completion
10 March 2028

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Incidence of severe late complications

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 21 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov